866-997-4948(US-Canada Toll Free)

Metastatic Ovarian Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Ovarian Cancer

No. of Pages : 49 Pages

 

Global Markets Directs, \'Metastatic Ovarian Cancer Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer. Metastatic Ovarian Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Metastatic Ovarian Cancer.
  • A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Ovarian Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Ovarian Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Ovarian Cancer 7
Metastatic Ovarian Cancer Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Metastatic Ovarian Cancer Therapeutics - Products under Development by Companies 14
Companies Involved in Metastatic Ovarian Cancer Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
Daiichi Sankyo Company, Ltd 16
Dainippon Sumitomo Pharma Co., Ltd. 17
Aphios Corporation 18
Northwest Biotherapeutics, Inc. 19
ThromboGenics NV 20
Metastatic Ovarian Cancer - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
tigatuzumab - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
TB-403 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
APH-0912 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
bevacizumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Tumor Adaptive Responses Program - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Tumor Microenvironment Program - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SM-276001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Pseudovirions For Cancer - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Metastatic Ovarian Cancer Therapeutics - Drug Profile Updates 39
Metastatic Ovarian Cancer Therapeutics - Discontinued Products 44
Metastatic Ovarian Cancer Therapeutics - Dormant Products 45
Metastatic Ovarian Cancer - Product Development Milestones 46
Featured News & Press Releases 46
Mar 18, 2013: Merrimack Pharma Completes Enrollment In Phase II Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-resistant Or Refractory Advanced Ovarian Cancers 46
Mar 06, 2013: Ziopharm Oncology Announces Initiation Of Indiana University-sponsored Phase II Study Of Palifosfamide In Recurrent And Incurable Germ Cell Tumors 46
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Of MM-121 At European Society For Medical Oncology 2012 47


Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Table


Number of Products Under Development for Metastatic Ovarian Cancer, H2 2013 7
Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Late Stage Development, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Clinical Stage Development, H2 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
F. Hoffmann-La Roche Ltd., H2 2013 15
Daiichi Sankyo Company, Ltd, H2 2013 16
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 17
Aphios Corporation, H2 2013 18
Northwest Biotherapeutics, Inc., H2 2013 19
ThromboGenics NV, H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 25
Metastatic Ovarian Cancer Therapeutics - Drug Profile Updates 39
Metastatic Ovarian Cancer Therapeutics - Discontinued Products 44
Metastatic Ovarian Cancer Therapeutics - Dormant Products 45

List of Chart


Number of Products under Development for Metastatic Ovarian Cancer, H2 2013 7
Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Late Stage Products, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Early Clinical Stage Products, H2 2013 12
Discovery and Pre-Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 21
Assessment by Route of Administration, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Molecule Type, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *